Triple negative breast cancer (TNBC) account for 12% to 17% of all breast cancers. It is a heterogeneous group of tumors associated with aggressive clinical course. Insulin-like growth factor II mRNA binding protein 3 (IMP3) belongs to a family of insulin-like growth factor type II (IGF2), which plays a key role in the transmission and stabilization of mRNA, cell growth, and migration during embryogenesis. Increased expression of IMP3 is associated with aggressive behavior of different tumor types, advanced clinical stage, distant metastasis, and shorter overall survival (OS).
Introduction
Triple negative breast cancer, accounting for 12% to 17% of all breast cancers, is a heterogeneous group of tumors associated with aggressive clinical course, blood borne liver, lung, and brain metastasis while metastases in loco regional lymph nodes are less common in comparison to other breast tumors types. [1] [2] [3] [4] Despite good initial response to neoadjuvant chemotherapy protocols, patients with this type of tumor have higher rates of distant metastases and ultimately poor prognosis. [1, 2, 5] Recently, substantial efforts were made toward improving treatment outcome for TNBC patients, requiring further subclassification based on prognostic value of new molecular biomarkers.
Insulin-like growth factor II mRNA binding protein 3 (IMP3) belongs to a family of insulin-like growth factor type II (IGF2), which plays a key role in the transfer and stabilization of mRNA, cell growth, and migration during embryogenesis. To date, there are three known members of IMP3 family proteins: IMP1, IMP2, and IMP3 [6] Expression of IMP3 is negative in normal, mature tissues, but was found as positive in the malignant tumors of the colon, kidney, bladder, pancreatic ductal adenocarcinoma, gastric cancer, non-small cell lung cancer, melanoma, thyroid cancer, osteosarcoma, and breast cancer and related with aggressive behavior of the tumor, advanced clinical stage, and distant metastases. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Recent studies have shown that IMP3 expression is closely associated with estrogen receptor negativity and positive expression of EGFR. [19] IMP3 acts as a promoter of aggressive behavior in triple negative breast cancer and contributes to breast cancer chemo resistance.
IMP3 binds to breast cancer resistance protein (BCRP) mRNA and regulates BCRP expression. BCRP, also known as ATPbinding cassette super-family G member 2 , is a member of the ATP-binding cassette (ABC) transporters and a major effector of resistance to doxorubicin and mitoxantrone in breast cancer. Depletion of IMP3 expression in triple-negative breast cancer cells increased significantly their sensitivity to doxorubicin and mitoxantrone. [20, 21] 2. Materials and methods
Patients
In our study, 118 patients with triple negative breast cancer, undergoing surgery between January 2003 and December 2009, who did not receive preoperative chemotherapy and had available paraffin embedded tissue blocks were reviewed retrospectively. Clinical information was collected through the breast cancer database of the Department of Oncology and Radiotherapy, Split University Clinical Center.
All histological and Immunohistochemistry (IHC) tumor slides were evaluated by two pathologists (ST, IM) and graded according to Elston and Ellis grading method. [22] Histological types were determined according to WHO and staged according to TNM Classification. [23, 24] Ethical committee for Biomedical Research of the Clinical Hospital Center Split approved that this research are in compliance with the Helsinki Declaration (reference number 49-1/06).
Immunohistochemical analysis
Sections from fixed, paraffin embedded, cancer tissues were stained by hematoxylin/eosin with additional immunostains for ER (1:200, Dako, Glostrup, Denmark), PR (1:100, Dako), epidermal growth factor receptor 2 (HER2/neu) (HercepTest assay, Dako), Ki-67 (1:200, Dako), and IMP3 (1:150, Dako).
Immunoassays were performed on Ventana BenchMark Ultra autostainer (Roche, Tucson, AZ). HER2 status was evaluated by IHC (Hercept Test, Dako, Glostrup, Denmark) or by chromogenic in situ hybridization (SPOT-Light HER2 CISH Kit, Invitrogen/ Zymed, Camarillo, CA). Tests were scored according to ASCO/ CAP guidelines. [25] ER and PR were considered positive if at least 1% of the invasive tumor cell nuclei were positive ( Fig. 1 ). [4] IMP3 staining was evaluated semiquantitatively according to finding of Brown staining in the cytoplasm. The intensity of staining was estimated as: absent (0), weak (1), moderate (2), and strong (3) cytoplasmic staining. The percentage of stained cells was scored: 0% (0), 1% to 25% (1), 25% to 50% (2), 51% to 75% (3), and 75% to 100% (4) . Based on the sum of the score obtained by evaluation of the intensity of staining and the percentage of stained cells the final sum was formed, and interpreted in the following way: 0 to 1 as negative staining, 2 to 4 as weak positive staining, and 5 to 7 as strong positive staining ( Fig. 1 ).
Basal like (BL) morphology was considered positive if characteristic features, such as syncytial growth pattern, high-mitotic index, large central acellular/necrotic zone, pushing borders, dense lymphocytic infiltrate at the periphery of the invasive component, and the presence of metaplastic and medullary elements were present ( Fig. 2 ). [26] Vascular invasion was considered positive if the presence of tumor cells in endothelium confined spaces on the periphery of the tumor was found (Fig. 2 ).
Ki-67 was scored by counting 1000 tumor cells using the Olympus Image Analyser (magnification 400Â), at the hot spots and at the periphery of the invasive component. Data are expressed as percentages of positive cells. [27] the IMP3 expression and tumor size, clinical stage, and basal morphology (P = .039, P = .034, P < .001, respectively ( Table 2) . Univariate survival analysis revealed that age (P = .030), clinical stage (P < .001), basal morphology (P = .001), and IMP staining (P < .001) statistically correlated with DFS (Table 3 ) ( Fig. 3) . Univariate survival analysis revealed that age (P = 0.034), clinical stage (P < .001), basal morphology (P = .001), and IMP3 staining (P < .001) statistically correlated with OS (Table 4 ) ( Fig. 4 ).
Multinominal analysis was performed which included all variables that yielded significant P-value by univariate analysis. Therefore, an independent prognostic relevance was found for tumor size, clinical stage, and IMP3 immunostaining.
Regarding DFS, statistically significant predictors were tumor size (RR = 1.64, P = .016), clinical stage (RR = 1.25, P = .049), and IMP3 staining (RR = 2.84, P = .001) ( Table 5 ). Multinomial analysis revealed that significant predictors for OS were tumor size (RR = 1.60, P = .022) and IMP3 (RR = 2.67, P = .001) ( Table 6 ).
Discussion
TNBC represents a heterogeneous group of tumors characterized by aggressive tumor biology responsible for poor survival outcomes in comparison with other breast cancer types and lack of targeted therapies, which is creating high unmet need for better understanding of TNBC molecular nature and development of new subclassification of this disease. [28] Discovering new biomarkers with potential prognostic and predictive value may trigger development of targeted therapies and ultimately improve TNBC outcome.
In our study the most common histological type was NOS (83.9%) and basal morphology was observed in 46.6% of TNBC, which is in concordance with results of previous studies. [28] [29] [30] Out of 118 patients 42 (35.6%) had positive expression of IMP3, and this finding is in concordance with the research of Walter et al. [31] Analysis of the relationship between IMP3 expression and histopathological parameters in our study revealed that positive IMP3 expression significantly correlated with greater tumor size, higher clinical stage and basal morphology which are clinical and pathological predictors of aggressive biologic behavior in breast cancer. The presence of vascular invasion was observed in 33.9% samples and there was no statistically significant correlation between vascular invasion and increased IMP3 expression. Mohammed et al have found that vascular invasion was more frequently present in TNBC versus non-TNBC tumors, as well in BL more than in non-BL ones. [32] In our study, survival analyses have shown no correlation between vascular invasion and OS and DFS. Possible explanation for this finding is that in this particularly aggressive type of breast cancer vascular invasion is losing its prognostic value. The vast majority (85%) of the TNBC in our study was associated with high-histologic grade, only 19.5% tumors were moderately differentiated, and none of the samples belonged to well-differentiated category, which could be the explanation for lack of correlation between IMP3 immunoexpression and histologic grade. Survival analysis that we performed revealed that DFS interval and OS in patients with triple negative breast cancer is shorter in cases of high-clinical stage, presence of basal morphology, and strong IMP3 immunostaining. Based on the Cox regression analysis, our study showed that increased expression of IMP3 is a negative predictive factor for the prognosis of triple negative breast cancer. According to our results, determination of IMP3 biomarker, may serve as independent prognostic factor within the heterogeneous group of triple negative breast cancer. In addition, IMP3 targeting could be efficient approach for TNBC management due to several reasons: IMP3 was not expressed in the normal tissue of the breast, the mechanism of action of this molecule is known (for the binding of sequence-specific RNA), and the inhibition of the expression of IMP3 molecule should increase the sensitivity of tumors to chemotherapy. IMP3 epitopes, based on their immunogenicity (i.e., the capacity to induce a strong and specific anti-tumor immune response), could be the target for the newly synthesized vaccine for the treatment of triple negative breast cancer. [33] [34] [35] Cancer vaccines are designed to target only cancer cells and provide sparing of surrounding healthy tissue. The results of recent clinical trials have shown their safety and almost non-existing risk of autoimmune reactivity when being tested for the treatment of lung cancers and esophageal cancers; activating IMP3 specific T-cell immune response in patients with the HLA-A 24-positive carcinoma of the esophagus and lung. [33, 36, 38] It is believed that the same mechanism of IMP3 specific T cell immune response represents a new possibility for the treatment of triple negative breast cancer.
